HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $8 Price Target

Benzinga · 1d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $8 price target.